Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
April 09 2008 - 9:00AM
PR Newswire (US)
SANTA MONICA, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Aida
Pharmaceuticals, Inc. (OTC:AIDA) (BULLETIN BOARD: AIDA) today
announced that its recently-acquired research institute in the
Jiangsu Province, the Jiangsu Institute of Microbiology Co., Ltd or
"JSIM", is developing a new wide-spectrum antibiotic, Wetimicin, in
the People's Republic of China. Wetimicin is from the newest
generation of amino-glycoside family of antibiotics and is being
tested for the treatment of various inflammations, such as
respiratory infection, urinogenital infection, soft skin tissue
infection as well as infections from trauma and operations, etc.
JSIM's scientists believe that it might be safer and more reliable
for children and elderly patients than current drug offerings in
the marketplace. Management believes that Wetimicin will have a
larger market volume than that of Etimicin Sulphate, the company's
current pillar product, which is in the same family of antibiotics
as Wetimicin, due to its potentially stronger applicability to a
wider range of ailments. Management's experience, resources and
marketing channels will play a key role in driving Wetimicin to
market approval and distribution. The research for this new drug
started in 2000 and it is currently undergoing Phase 1 clinical
trials in conjunction with the Chinese government's State Food and
Drug Administration ("SFDA"). The company believes that Phase 2
testing will commence some time in 2008. The company will have the
right of first refusal of the manufacturing and marketing of the
drug once it is approved by the SFDA as a Category A innovative new
drug. About Aida Pharmaceuticals, Inc. Aida Pharmaceuticals, Inc.
is a product-focused pharmaceuticals company engaged in the
formulation, clinical testing, registration, manufacture, sales and
marketing of advanced pharmaceutical and genetic products in
mainland China. The Company's mission is to discover, develop and
market meaningful new therapies that improve human health. Aida
Pharmaceuticals, in operation since March 1999, is headquartered in
Hangzhou, People's Republic of China with manufacturing,
distribution and sales points throughout mainland China. Aida
Pharmaceuticals, Inc. is GMP-certified in the People's Republic of
China and ISO9002-certified for quality assurance and ISO14000
certified for ecologically-friendly practices. For additional
information, please visit http://en.aidapharma.com/. Safe Harbor
Statement Under The Private Securities Litigation Reform Act of
1995: Except for historical information contained herein, the
statements in this news release are forward-looking statements that
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause a company's actual results, performance and achievement
in the future to differ materially from forecasted results,
performance, and achievement. These risks and uncertainties are
described in the Company's periodic filings with the Securities and
Exchange Commission. The Company undertakes no obligation to
publicly release the result of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof, or to reflect the occurrence
of unanticipated events or changes in the Company's plans or
expectations. DATASOURCE: Aida Pharmaceuticals, Inc. CONTACT:
Ashley Hull, +1-310-450-9100, opt. 1, , for Aida Pharmaceuticals,
Inc.; or Broker Contact, Chesapeake Group, +1-410-825-3930, for
Aida Pharmaceuticals, Inc. Web site: http://en.aidapharma.com/
Copyright